CBD2 Receptors: Unmasking Cancer’s Silent Targets

Here’s what we understand:

* CBD2 Receptors in Cancer: Elevated CBD2 receptor expression can lead to increased immune infiltration, but paradoxically, it results in immune suppression and evasion, allowing cancer to metastasize more easily within the tumor microenvironment.

* Cancer Types with Increased CBD2 Expression:
* Breast Cancer: Particularly aggressive forms like triple-negative breast cancer (TNBC) and inflammatory breast cancer.
* Glioblastoma: One of the most aggressive brain cancers.
* Non-Small Cell Lung Cancer (NSCLC).
* Prostate Cancer: Especially in more aggressive forms of the disease.
* Colon Cancer: Colorectal carcinomas showing higher CBD2 levels.
* Liver Cancer (Hepatocellular Carcinoma).
* Pancreatic Cancer: Notoriously difficult to treat, with low survival rates.
*
The Good News:
* CBD (Cannabidiol) can interact with these CBD2 receptors. Acting as a negative allosteric modulator, CBD binds to a different site on the receptor, decreasing its immune-suppressing effects.

By utilizing CBD, we can:
* Reduce Immune Suppression: Enhancing the body’s ability to fight back.
* Empower the Immune System: Allowing immune cells to recognize and attack cancer cells more effectively.
* Leverage CBD2 Expression Against Cancer: Turning what was once a silent target into a focal point for therapy.

At the Williams Cancer Institute, we harness the power of the immune system through an intratumoral immune approach.

Click the link in my bio to schedule a free consultation with us at the Williams Cancer Institute.

#CancerResearch #CBD #CBD2 #CancerTreatment #IntegrativeOncology #WilliamsCancerInstitute #Immunotherapy #BreastCancer #Glioblastoma #LungCancer #ProstateCancer #ColorectalCancer #PancreaticCancer #HealthInnovation #HealingJourney #FightCancer #HolisticHealth